The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer

Figures & data

Figure 1. Schematic flow diagram for selection of included studies

Table 1. Characteristics of the included studies

Study	Year	No. of patients	Percentage of mutation	Mutation point	Type of bladder cancer	Follow up time	Sample types
Roggisch, J [19]	2020	75	63 (84.0%)	C288T&C250T	urothelial	53	tissue
Hayashi, Y [17]	2020	54	16 (29.6%)	C288T&C250T	urothelial	60	tissue
Yujiro, H [16]	2020	35	6 (17.4%)	C288T&C250T	urothelial	72	urine
Batista, R [13]	2020	125	70 (56.0%)	C288T&C250T	urothelial	150	tissue
Leao, R [18]	2019	237	182 (76.8%)	not mentioned	urothelial	200	tissue
Descotes, F [15]	2017	348	280 (80.5%)	C288T&C250T	urothelial	60	urine
Critelli, R [14]	2016	229	119 (52.0%)	C288T&C250T	urothelial	96	urine
Rachakonda, P [6]	2013	279	186 (66.7%)	C288T&C250T	urothelial	180	tissue

Figure 2. Methodological quality of the retrospective studies

Figure 3. Forest plot of the HR analysis of TERT promoter mutation with RFS and OS of BC. A forest plot of RFS; B forest plot of OS

Figure 4. Begg’s funnel plots, and sensitivity analysis of the HR analysis of TERT promoter mutation with RFS and OS of BC. A funnel plot of RFS; B sensitivity analysis of RFS; C funnel plot of OS; D sensitivity analysis of OS

Figure 5. Case number subgroup analysis of the HR analysis of TERT promoter mutation with RFS of BC

Figure 6. Specimen’s subgroup analysis of the HR analysis of TERT promoter mutation with RFS of BC

Roggisch J, Ecke T, Koch S. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urol Oncol. 2020;38(3):77.e17–77.e25.

 PubMed Web of Science ®Google Scholar

Hayashi Y, Fujita K, Nojima S, et al. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol Oncol. 2020;14(10):2375–2383.

 PubMed Web of Science ®Google Scholar

Hayashi Y, Fujita K, Matsuzaki K, et al. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front Oncol. 2020;10:755.

 PubMed Web of Science ®Google Scholar

Batista R, Lima L, Vinagre J, et al. TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients. Int J Mol Sci. 2020;21(3):3.

 Web of Science ®Google Scholar

Leão R, Lee D, Figueiredo A, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019;144(7):1676–1684.

 PubMed Web of Science ®Google Scholar

Descotes F, Kara N, Decaussin-Petrucci M, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117(4):583–587.

 PubMed Web of Science ®Google Scholar

Critelli R, Fasanelli F, Oderda M, et al. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget. 2016;7(41):67435–67448. .

 PubMedGoogle Scholar

Rachakonda PS, Hosen I, De Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110(43):17426–17431.

 PubMed Web of Science ®Google Scholar